Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Modified-release (MR) trazodone formulations (prolonged-release [PR] and once-a-day [OAD]) are used to treat acute major depressive disorder (MDD), but there has been no quantitative synthesis of the available double-blind randomized evidence. We assessed the efficacy and tolerability of MR trazodone in adults with acute MDD. METHODS: We searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov up to 24 February 2026 and Scopus up to 6 March 2026. We also screened the reference lists of the identified publications for randomized controlled trials (RCTs) of trazodone PR or OAD in adults with acute MDD. Random-effects meta-analyses were performed when at least 2 trials were available. FINDINGS: Five primary RCTs (N=1329 randomized) met the inclusion criteria: 2 were placebo-controlled and 3 were active-controlled. Compared with placebo, MR trazodone improved HAM-D-17 scores (mean difference in symptom improvement: 2.49; 95% CI: 1.48-3.51) and increased the response rate (risk ratio [RR]: 1.44; 95% CI: 1.19-1.75). Remission rates were higher but imprecise (RR: 1.32; 95% CI: 0.93-1.88). Discontinuation due to adverse events occurred more frequently than with placebo (RR: 3.57; 95% CI: 1.79-7.10). In head-to-head trials, the estimates versus SSRIs were imprecise and did not demonstrate equivalence. A single venlafaxine XR trial favored venlafaxine. CONCLUSIONS: On the basis of 2 placebo-controlled trials, MR trazodone was found to be more effective than a placebo for reducing acute adult MDD symptoms in the short term. Sparse active-comparator evidence does not demonstrate superiority or equivalence compared with standard antidepressants. Real-world data may provide complementary information when insomnia or anxious distress is prominent.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Psychopharmacology
Published
2026-11-18
DOI
https://doi.org/10.1097/jcp.0000000000002299
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Fabiola Raffone, Vassilis Martiadis, Enrico Pessina, Azzurra Martini et al.
3 links
Journal of Clinical Psychopharmacology
Treatment of Major Depression
article

Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Fabiola Raffone, Vassilis Martiadis, Enrico Pessina, Azzurra Martini, Antonella Cervino
article en

Abstract

BACKGROUND: Modified-release (MR) trazodone formulations (prolonged-release [PR] and once-a-day [OAD]) are used to treat acute major depressive disorder (MDD), but there has been no quantitative synthesis of the available double-blind randomized evidence. We assessed the efficacy and tolerability of MR trazodone in adults with acute MDD. METHODS: We searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov up to 24 February 2026 and Scopus up to 6 March 2026. We also screened the reference lists of the identified publications for randomized controlled trials (RCTs) of trazodone PR or OAD in adults with acute MDD. Random-effects meta-analyses were performed when at least 2 trials were available. FINDINGS: Five primary RCTs (N=1329 randomized) met the inclusion criteria: 2 were placebo-controlled and 3 were active-controlled. Compared with placebo, MR trazodone improved HAM-D-17 scores (mean difference in symptom improvement: 2.49; 95% CI: 1.48-3.51) and increased the response rate (risk ratio [RR]: 1.44; 95% CI: 1.19-1.75). Remission rates were higher but imprecise (RR: 1.32; 95% CI: 0.93-1.88). Discontinuation due to adverse events occurred more frequently than with placebo (RR: 3.57; 95% CI: 1.79-7.10). In head-to-head trials, the estimates versus SSRIs were imprecise and did not demonstrate equivalence. A single venlafaxine XR trial favored venlafaxine. CONCLUSIONS: On the basis of 2 placebo-controlled trials, MR trazodone was found to be more effective than a placebo for reducing acute adult MDD symptoms in the short term. Sparse active-comparator evidence does not demonstrate superiority or equivalence compared with standard antidepressants. Real-world data may provide complementary information when insomnia or anxious distress is prominent.

Journal of Clinical Psychopharmacology
University of Campania "Luigi Vanvitelli" (IT), Regione Campania (IT), ASL Roma (IT), Azienda Sanitaria Locale Salerno (IT)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon